Medtronic ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed 780G system¹, compared to insulin injections

First-of-its-kind study demonstrates individuals using the Medtronic system achieved 1.4% absolute reduction in A1c and 27.6% absolute increase in Time in Range

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced results from the Medtronic ADAPT study were published in The Lancet Diabetes & Endocrinology . The ADAPT study is the first multi-national randomized controlled study evaluating the performance of MiniMed™ 780G system 1 versus standard of care (multiple daily injections (MDI) + continuous glucose monitoring (CGM)) in individuals with type 1 diabetes not currently meeting glycemic targets. The study evaluated 82 individuals who were using MDI and an intermittently scanned continuous glucose monitor (isCGM) to manage their diabetes prior to trial initiation. On average, individuals enrolled were scanning their isCGM frequently (~9 scansday) yet had suboptimal HbA1C above 8% at baseline.

At study initiation, half of the participants were randomized to stay on standard of care, and the rest transitioned directly to the MiniMed 780G system. Study results showed improvement in glycemic targets for those that transitioned to the MiniMed 780G system with a significant and sustained 1.4% HbA1C reduction at six months. Those using the Medtronic system also saw a 27.6% absolute increase in Time in Range (6.6 more hours/day in target range) compared to those on standard of care without increased in time in hypoglycemia. This improvement was even greater overnight when the algorithm was in full control.

Time in Range Improvements for Those That Transitioned to the

MiniMed 780G System


Standard of Care

(MDI + isCGM)

MiniMed 780G System



Baseline

Study
Results

Baseline

Study
Results

Difference

Mean Sensor

Glucose (SG)

195.1 mg/dL

194.7 mg/dL

208.8 mg/dL

152.2 mg/dL

-44.9 mg/dL

Overall TIR

(70 – 180 mg/dL)

42.6 %

43.6 %

36.4 %

70.6 %

+27.6 %

Daytime TIR

-

43.0 %

-

68.8 %

+26.2 %

Overnight TIR

-

46.6 %

-

76.2 %

+30.2 %

"The ADAPT study illustrates that insulin pump therapy with advanced algorithms, like that of the MiniMed 780G system, can produce significantly improved clinical results versus the current standard of care," said Ohad Cohen , M.D., senior global medical affairs director, Medtronic Diabetes. "Studies like this can change how health care systems define standard of care and expand options for people living with diabetes to begin using insulin pumps sooner to improve their glycemic control and help reduce the burden of diabetes."

When comparing A1C results at 6 months, 27.8% of individuals using the MiniMed 780G system in the study achieved an HbA1c below 7%, while no individuals that remained on MDI +isCGM achieved that desired result.

Significantly More Participants Achieved Glycemic Targets at 6 Months

with the MiniMed 780G System


Standard of Care

(MDI + isCGM)

MiniMed 780G System

Difference

HbA1C

0 %

27.8 %

+25.2 %

TIR > 70%

6.5 %

52.8 %

51.1 %

In terms of customer experience, participants using the MiniMed 780G system spent 95.8% of the time in SmartGuard™ (advanced hybrid closed-loop) and experienced few system exits (only 0.9 SmartGuard exits/week. Additionally, the sensor was being used 92.2% of the time (vs. 87.3% in the standard of care group). The ADAPT study also showed that those that transitioned to the MiniMed 780G system experienced a significant increase in treatment satisfaction 2 and reduction in fear of hypoglycemia 3 .

Overall, results showed that the use of the MiniMed 780G system, even when paired with the Guardian™ sensor 3 which requires two fingerstick calibrations per day, had significant improvement across all glycemic metrics compared to standard of care and supports the use at early stages in the treatment pathway given the potential benefits of complication avoidance 4 , treatment satisfaction improvements, and reduced fear of hypoglycemia.

The MiniMed 780G system is now available in over 60 countries around the world and is currently being reviewed by the Food and Drug Administration (FDA) for approval in the U.S.

About the MiniMed 780G system
The MiniMed 780G system is the most advanced insulin pump system from Medtronic, currently approved for the treatment of type 1 diabetes in people aged 7 to 80 years. The MiniMed 780G system's SmartGuard algorithm (also referred to as the advanced hybrid closed-loop algorithm) automates the delivery of insulin every five minutes — personalizing these doses to auto-correct highs every five minutes based on CGM readings 5,6 . The system is designed to be used at a target glucose of 100 mg/dl (5.5 mmol/L) that can be adjusted and personalized on an individual basis.

About the Diabetes Business at Medtronic ( www.medtronicdiabetes.com )
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 MiniMed 780G System and Guardian™ 4 sensors are CE Marked only and not commercially available or approved in the U.S.
2 Patient reported outcomes within the ADAPT Study: Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Fear of Hypoglycemia (FHS) Survey
3 Mean DTSQs score for AHCL vs MDI+isCGM arm (6.1 ± 7.55 vs 0.2 ± 6.84, p=0.0003), and HFS scores for AHCL vs MDI+isCGM (-10.2 ± 15.51 vs -2.7 ± 13.08, p = 0.0409)
4 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus NIH external link. New England Journal of Medicine. 1993;329(14):977–986.
5 Carlson, A.L. et al. Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop system pivotal trial in adolescents and adults with type 1 diabetes. Diab Tech Ther 2021; in press.
6 Collyns.O. et al. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes . Diab Care 2021, 44: 969-975

Contacts:




Kendra Cassillo

Ryan Weispfenning

Public Relations

Investor Relations

+1-818-576-5611

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-adapt-study-results-published-in-the-lancet-diabetes--endocrinology-show-improved-glycemic-control-and-treatment-satisfaction-among-those-using-minimed-780g-system-compared-to-insulin-injections-301613854.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/September2022/01/c9635.html

News Provided by Canada Newswire via QuoteMedia

MDT
The Conversation (0)

PrairieSky Announces Fourth Quarter And Year-End Results For 2023, Including Record Oil Royalty Production, Strong Leasing Activity And Increased Annual Dividend

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its fourth quarter (" Q4 2023 ") and year-end operating and financial results for the period ended December 31, 2023. PrairieSky is also pleased to announce a 4% increase in its annual dividend to $1.00 per common share ($0.25 per common share quarterly).

Fourth Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces 2023 Third Quarter Results

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its third quarter (" Q3 2023 ") results for the three-month period ended September 30, 2023.

Third Quarter Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less

PrairieSky Announces 2023 Second Quarter Results, Including Record Oil Royalty Production

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its second quarter (" Q2 2023 ") results for the three-month period ended June 30, 2023.

Second Quarter Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×